PMID- 21258428 OWN - NLM STAT- MEDLINE DCOM- 20111121 LR - 20211020 IS - 1868-8500 (Electronic) IS - 1868-8497 (Print) IS - 1868-8497 (Linking) VI - 1 IP - 5 DP - 2010 Oct TI - Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. PG - 229-44 LID - 10.1007/s12672-010-0048-0 [doi] AB - Both estrogen (E) and progesterone (P) are implicated in the etiology of human breast cancer. Defining their mechanisms of action, particularly in vivo, is relevant to the prevention and therapy of breast cancer. We investigated the molecular and cellular mechanisms of E and/or P-induced in vivo proliferation, in the normal rat mammary gland and in hormone-dependent rat mammary cancers which share many characteristics with the normal human breast and hormone-dependent breast cancers. We show that E+P treatment induced significantly greater proliferation in both the normal gland and mammary cancers compared to E alone. In both the normal gland and tumors, E+P-induced proliferation was mediated through the increased production of amphiregulin (Areg), an epidermal growth factor receptor (EGFR) ligand, and the activation of intracellular signaling pathways (Erk, Akt, JNK) downstream of EGFR that regulate proliferation. In vitro experiments using rat primary mammary organoids or T47D breast cancer cells confirmed that Areg and the synthetic progestin, R5020, synergize to promote cell proliferation through EGFR signaling. Iressa, an EGFR inhibitor, effectively blocked this proliferation. These results indicate that mediators of cross talk between E, P, and EGFR pathways may be considered as relevant molecular targets for the therapy of hormone-dependent breast cancers, especially in premenopausal women. CI - (c) The Author(s) 2010. This article is published with open access at Springerlink.com. FAU - Kariagina, Anastasia AU - Kariagina A AD - Department of Physiology, Breast Cancer and the Environment Research Center, Michigan State University, 2201 Biomedical & Physical Sciences Bldg, East Lansing, MI, USA. FAU - Xie, Jianwei AU - Xie J FAU - Leipprandt, Jeffrey R AU - Leipprandt JR FAU - Haslam, Sandra Z AU - Haslam SZ LA - eng GR - U01 ES012800/ES/NIEHS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20101123 PL - United States TA - Horm Cancer JT - Hormones & cancer JID - 101518427 RN - 0 (AREG protein, human) RN - 0 (Amphiregulin) RN - 0 (Areg protein, rat) RN - 0 (EGF Family of Proteins) RN - 0 (Estrogens) RN - 0 (Glycoproteins) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 4G7DS2Q64Y (Progesterone) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Amphiregulin MH - Animals MH - Blotting, Western MH - Cell Line, Tumor MH - Cell Proliferation MH - EGF Family of Proteins MH - ErbB Receptors/*metabolism MH - Estrogens/*metabolism MH - Female MH - Gene Expression Regulation/physiology MH - Glycoproteins/*metabolism MH - Humans MH - Immunohistochemistry MH - Intercellular Signaling Peptides and Proteins/*metabolism MH - Mammary Glands, Animal/metabolism MH - Mammary Neoplasms, Experimental/*metabolism MH - Neoplasms, Hormone-Dependent/metabolism MH - Progesterone/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Real-Time Polymerase Chain Reaction MH - Reverse Transcriptase Polymerase Chain Reaction MH - Signal Transduction/*physiology PMC - PMC3000471 COIS- The authors declare that they have no conflict of interests. EDAT- 2011/01/25 06:00 MHDA- 2011/12/13 00:00 PMCR- 2010/11/23 CRDT- 2011/01/25 06:00 PHST- 2011/01/25 06:00 [entrez] PHST- 2011/01/25 06:00 [pubmed] PHST- 2011/12/13 00:00 [medline] PHST- 2010/11/23 00:00 [pmc-release] AID - 48 [pii] AID - 10.1007/s12672-010-0048-0 [doi] PST - ppublish SO - Horm Cancer. 2010 Oct;1(5):229-44. doi: 10.1007/s12672-010-0048-0. Epub 2010 Nov 23.